{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:38:43Z","timestamp":1773337123663,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriatic arthritis (PsA) is a heterogeneous, immune-mediated disease affecting joints, entheses, the axial skeleton, and skin. Although many targeted therapies have emerged, unmet needs remain in musculoskeletal control, comorbidity management, and durable remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To map the contemporary clinical-trial landscape of PsA pharmacotherapy and place these data in the context of current evidence, treatment guidelines, regulatory changes, and translational advances.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed Citeline Trialtrove data on 587 interventional PsA drug trials initiated from 1999 to 2025. Structured variables captured annual trial starts by phase, operational status and outcomes, geographic distribution, funding sources, investigated drugs, molecular targets, and primary endpoints. We characterized trends using descriptive statistics and graphical summaries. To strengthen interpretation of temporal trends, we additionally prespecified count-based trend testing (Poisson\/negative binomial regression) and conducted era-stratified summaries (1999\u20132010 vs 2011\u20132025) to reflect systemic changes in regulation and transparency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Trial activity was higher after 2012, with increased early-phase programs and sustained phase III\/IV development. Most studies reached completion (82.5%); 22.7% disclosed positive outcomes, while many were labeled undefined because of incomplete or non-standardized reporting. Terminations were driven mainly by business decisions rather than lack of efficacy. The United States (US) and China had the highest absolute trial participation, with Europe providing strong multicenter coordination; population-standardized participation (trials per 10 million population) was higher in the US than in China. Funding was diverse: academic institutions (35.3%) and top-20 pharmaceutical companies (32.9%) predominated, alongside smaller industry and generic sponsors. TNF inhibitors such as adalimumab and etanercept were the most frequently tested agents, but substantial activity involved newer mechanisms including IL-17\/IL-23, JAK1\/TYK2, and PDE4 pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Over the past two decades PsA drug development has broadened from TNF blockade to multiple targeted axes, supported by balanced academic\u2013industry sponsorship and a rapidly expanding global footprint. Yet challenges remain\u2014heterogeneous endpoints, incomplete outcome reporting, modest musculoskeletal efficacy in some novel classes, and the need to integrate cost considerations as biosimilars and generics enter routine care. Future trials should prioritize harmonized, domain-specific outcomes, precision patient selection, long-term safety (especially for JAK-pathway inhibitors), and pragmatic, treat-to-target designs to translate mechanistic advances into sustainable, patient-centered therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1722103","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:46:26Z","timestamp":1773297986000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug development in psoriatic arthritis: a trialtrove-based landscape analysis (1999\u20132025)"],"prefix":"10.3389","volume":"17","author":[{"given":"Gang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Rehabilitation Medicine, the First Medical Center, Chinese People\u2019s Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, the First Medical Center, Chinese People\u2019s Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinling","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, the First Medical Center, Chinese People\u2019s Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuangwei","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, the First Medical Center, Chinese People\u2019s Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuting","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, the First Medical Center, Chinese People\u2019s Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, the First Medical Center, Chinese People\u2019s Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, the First Medical Center, Chinese People\u2019s Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, the First Medical Center, Chinese People\u2019s Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, the First Medical Center, Chinese People\u2019s Liberation Army (PLA) General Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e081860","DOI":"10.1136\/bmj-2024-081860","article-title":"Advances in the management of psoriatic arthritis in adults","volume":"387","author":"Kharouf","year":"2024","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"29711","DOI":"10.1038\/s41598-025-14790-7","article-title":"Sociodemographic factors and biologic therapy exposure impacting health-related quality of life in psoriatic arthritis - findings from a nationwide registry Reuma","volume":"15","author":"Santos","year":"2025","journal-title":"pt Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X241295920","article-title":"The impact of psoriatic arthritis on quality of life: a systematic review","volume":"16","author":"James","year":"2024","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.860813","article-title":"Histopathology of psoriatic arthritis Synovium-A narrative review","volume":"9","author":"Tenazinha","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol Int"},{"key":"B7","first-page":"19","article-title":"Diagnostic delay of psoriatic arthritis of more than six months contributes to poor patient-reported outcome measures in depression, social ability, and disease impact: A cross-sectional study","volume":"17","author":"Zundell","year":"2024","journal-title":"J Clin Aesthet Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225534","article-title":"Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"83","author":"Kerschbaumer","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01127-3","article-title":"Two sides of management recommendations for psoriatic arthritis","volume":"20","author":"Lubrano","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"31574","DOI":"10.1038\/s41598-025-15175-6","article-title":"Targeting dendritic cell-specific TNFR2 improves skin and joint inflammation in a murine model of psoriatic arthritis","volume":"15","author":"Kaur","year":"2025","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01083-y","article-title":"Difficult-to-treat psoriatic arthritis: moving out of the rheumatoid arthritis shadow","volume":"20","author":"Siebert","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0193088","DOI":"10.1371\/journal.pone.0193088","article-title":"Prevalence of clinical trial status discrepancies: A cross-sectional study of trials registered on both EUCTR and ClinicalTrials.gov","volume":"13","author":"Fleminger","year":"2018","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(24)00514-X","article-title":"Reporting summary results in clinical trial registries: updated guidance from WHO","volume":"13","author":"Chan","year":"2025","journal-title":"Lancet Glob Health"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-022-03630-y","article-title":"Clinical trials with investigational medicinal products-initial experiences with the new EU clinical trial regulation 536\/2014 and challenges and opportunities for contract research organisations","volume":"66","author":"Chase","year":"2023","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041312","article-title":"Therapeutic advancements in psoriasis and psoriatic arthritis","volume":"14","author":"Yi","year":"2025","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae198","article-title":"The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis","volume":"63","author":"Lembke","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14805","article-title":"Chinese Registry of Psoriatic Arthritis (CREPAR): I. Clinical characteristics of Chinese patients with psoriatic arthritis","volume":"26","author":"Lu","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25574","article-title":"Race, ethnicity, and geographic diversity in pivotal psoriatic arthritis clinical trials: further progress needed","volume":"77","author":"Choufani","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.43302","article-title":"Global recruiting patterns affect placebo response rates in clinical trials of psoriatic arthritis and plaque psoriasis","volume":"78","author":"Kerschbaumer","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0522","article-title":"GRAPPA 2021 treatment recommendations for psoriatic arthritis","volume":"50","author":"Soriano","year":"2023","journal-title":"J Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"24922","DOI":"10.1038\/s41598-024-75190-x","article-title":"Cycling versus swapping strategies with TNF-\u03b1 inhibitors and IL-17 inhibitors in psoriatic arthritis in clinical practice","volume":"14","author":"Lumetti","year":"2024","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218186","article-title":"IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors","volume":"80","author":"Nerviani","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish Nationwide DANBIO Registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01585-7","article-title":"Efficacy of tofacitinib in the treatment of psoriatic arthritis: A systematic review","volume":"38","author":"Gratac\u00f3s Masmitj\u00e0","year":"2021","journal-title":"Adv Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/e7ayu8","article-title":"JAK\/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis","volume":"39","author":"Crispino","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.42519","article-title":"Efficacy and safety of the TYK2\/JAK1 inhibitor brepocitinib for active psoriatic arthritis: A phase IIb randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/14712598.2022.2156283","article-title":"Emerging therapies for the treatment of spondyloarthritides with focus on axial spondyloarthritis","volume":"23","author":"Braun","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27154964","article-title":"An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022","volume":"27","author":"Crocetti","year":"2022","journal-title":"Molecules"},{"key":"B32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1186\/s40001-025-02995-5","article-title":"Relative sensitivity and preference of indicators in pharmaceutical trials of psoriasis and psoriatic arthritis","volume":"30","author":"Kang","year":"2025","journal-title":"Eur J Med Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1722103\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:46:27Z","timestamp":1773297987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1722103\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2026.1722103"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1722103","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1722103"}}